化学性质：                                                                                                             

产品描述：                                                                                                            

SB239063 is a potent and selective p38 MAPK inhibitor with an IC50 of 44 nM against p38α MAPK while exihibited no activity against the γ- and δ-kinase isoforms [1].

In vitro: In oxygen-glucose-deprived hippocampal slice cultures, treatment with 20 μM and 100 μM SB239063 significantly reduced the levels of the pro-inflammatory cytokine IL-1β and reduced cell death after oxygen-glucose deprivation and strikingly diminished microglia activation[2].

In vivo: Oral administration of 3–30 mg/kg SB 239063 given twice a day dose-dependently inhibited airway neutrophil infiltration and interleukin (IL)-6 levels 48 h after lipopolysaccharide (LPS) inhalation [1]. In a bleomycin-induced pulmonary fibrosis model rats, SB 239063 treatment (2.4 or 4.8 mg/day via osmotic pump) significantly inhibited bleomycin-induced right ventricular hypertrophy (indicative of secondary pulmonary hypertension) and increased in lung hydroxyproline synthesis (indicative of collagen synthesis and fibrosis) (1). In conscious guinea pigs, administration of SB 239063 (10 or 30 mg/kg p.o.) showed approximately 50% inhibition of OA-induced pulmonary eosinophil influx, measured by BAL 24 h after antigen(1). Orally administration of SB 239063 (30 mg/kg) attenuated IL-6 bronchoalveolar lavage fluid concentrations (> 90% inhibition) and MMP-9 activity (64% inhibition) measured 6 h after LPS exposure. In guinea pig cultured alveolar macrophages, SB 239063 inhibited LPS-induced IL-6 production with IC50 of 362 nM. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited IL-1 and TNF-α production with an IC50 of 0.12 and 0.35 μM, respectively(1).

特别提醒：